A Phase 1/2 interventional study of GSK3965193 and Placebo to match GSK3965193 in Hepatitis B, sponsored by GlaxoSmithKline. Terminated at 14 sites in 6 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · GlaxoSmithKline.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 25th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2022, is one of 2 in phase 1/2, and was the 26th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline is open now. Recruiting first, the newest first:
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 8 · Phase 4 10
First in 2000; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 163 across the 28 interventional studies, 172 across the 2 observational. Of the 28 that completed or were terminated, 18 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Hepatitis B, Chronic by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1/2a multiple part study is a first time-in-human (FTIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single (Part 1) and repeat doses (Part 2) of GSK3965193 in healthy participants. Part 3 will evaluate the ability of GSK3965193 to lower hepatitis B virus surface antigen (HBsAg) in participants living with chronic hepatitis B infection (PLWCHB) and will be given the option to subsequently receive treatment with open label bepirovirsen. Part 4 will evaluate the safety and tolerability of combination therapy with GSK3965193 and bepirovirsen and the potential to effect sustained virologic response in PLWCHB.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
This study's enrollment of 74 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Parts 1 and 2: Participants between 18 and 55 years of age inclusive, at the time of signing the .
Exclusion Criteria:
Exclusion Criteria for Healthy Participants:
Exclusion Criteria for PLWCHB:
Exclusion Criteria for PLWCHB:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants received a single dose of placebo oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 2 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 3 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 4 oral solution on Day 1 in Treatment Period 4. Dose 4 of GSK3965193 was higher than Dose 3 and Dose 3 was higher than Dose 2.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received a single dose of GSK3965193 Dose 1 oral solution on Day 1 in Treatment Period 1; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 3 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 4 oral solution on Day 1 in Treatment Period 4. Dose 4 of GSK3965193 was higher than Dose 3 and Dose 3 was higher than Dose 1.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received a single dose of GSK3965193 Dose 1 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 2 oral solution on Day 1 in Treatment Period 2; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 4 oral solution on Day 1 in Treatment Period 4. Dose 4 of GSK3965193 was higher than Dose 2 and Dose 2 was higher than Dose 1.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received a single dose of GSK3965193 Dose 1 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 2 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 3 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of placebo oral solution on Day 1 in Treatment Period 4. Dose 3 of GSK3965193 was higher than Dose 2 and Dose 2 was higher than Dose 1.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received a single dose of placebo oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 6 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 7 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 8 oral solution on Day 1 in Treatment Period 4. Dose 8 of GSK3965193 was higher than Dose 7 and Dose 7 was higher than Dose 6.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received a single dose of GSK3965193 Dose 5 oral solution on Day 1 in Treatment Period 1; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 7 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 8 oral solution on Day 1 in Treatment Period 4. Dose 8 of GSK3965193 was higher than Dose 7 and Dose 7 was higher than Dose 5.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received a single dose of GSK3965193 Dose 5 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 6 oral solution on Day 1 in Treatment Period 2; followed by a single dose of placebo oral solution on Day 1 in Treatment Period 3; further followed by a single dose of GSK3965193 Dose 8 oral solution on Day 1 in Treatment Period 4. Dose 8 of GSK3965193 was higher than Dose 6 and Dose 6 was higher than Dose 5.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received a single dose of GSK3965193 Dose 5 oral solution on Day 1 in Treatment Period 1; followed by a single dose of GSK3965193 Dose 6 oral solution on Day 1 in Treatment Period 2; followed by a single dose of GSK3965193 Dose 7 oral solution on Day 1 in Treatment Period 3; further followed by a single dose of placebo oral solution on Day 1 in Treatment Period 4. Dose 7 of GSK3965193 was higher than Dose 6 and Dose 6 was higher than Dose 5.
Drug: GSK3965193 · Drug: Placebo to match GSK3965193
Healthy participants received repeat doses of placebo oral solution twice daily (BID) for 14 days.
Drug: Placebo to match GSK3965193
Healthy participants received repeat doses of GSK3965193 Dose 9 oral solution BID for 14 days. Dose 9 of GSK3965193 was higher than Dose 4 but lower than Dose 5.
Drug: GSK3965193
Healthy participants received repeat doses of GSK3965193 Dose 5 oral solution BID for 14 days. Dose 5 of GSK3965193 was higher than Dose 9 but lower than Dose 10.
Drug: GSK3965193
Healthy participants received repeat doses of GSK3965193 Dose 6 oral solution BID for 14 days. Dose 6 of GSK3965193 was higher than Dose 10 but lower than Dose 7.
Drug: GSK3965193
Healthy participants received GSK3965193 Dose 10 oral tablets under fasted condition in Treatment Period 1, followed by GSK3965193 Dose 10 oral tablets under fed condition in Treatment Period 2. Dose 10 of GSK3965193 was higher than Dose 5 but lower than Dose 6.
Drug: GSK3965193
Healthy participants received GSK3965193 Dose 10 oral tablets under fed condition in Treatment Period 1, followed by GSK3965193 Dose 10 oral tablets under fasted condition in Treatment Period 2. Dose 10 of GSK3965193 was higher than Dose 5 but lower than Dose 6.
Drug: GSK3965193
Participants living with chronic hepatitis B infection (PLWCHB) on stable nucleos(t)ide analog (NA) therapy received repeat doses of placebo oral tablets for 28 days. Participants who completed placebo monotherapy were given the option to receive subsequent treatment of optional open label bepirovirsen subcutaneous (SC) injection from Day 43.
Drug: Placebo to match GSK3965193 · Drug: Bepirovirsen
PLWCHB on stable NA therapy received repeat doses of GSK3965193 Dose 9 oral tablets for 28 days. Participants who completed GSK3965193 monotherapy were given the option to receive subsequent treatment of optional open label bepirovirsen SC injection from Day 43. Dose 9 of GSK3965193 was higher than Dose 4 but lower than Dose 5.
Drug: GSK3965193 · Drug: Bepirovirsen
PLWCHB on stable NA therapy were planned to receive placebo oral tablets plus bepirovirsen SC injection for 28 days. All participants were further planned to continue receiving bepirovirsen SC injection after 28 days.
Drug: Placebo to match GSK3965193 · Drug: Bepirovirsen
PLWCHB on stable NA therapy were planned to receive GSK3965193 oral tablets plus bepirovirsen SC injection for 28 days. All participants were further planned to continue receiving bepirovirsen SC injection after 28 days.
Drug: GSK3965193 · Drug: Bepirovirsen
GSK3965193 was administered
Placebo to match GSK3965193 was administered
Bepirovirsen was administered
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Treatment Emergent Adverse Events (STEAEs), and Treatment Withdrawals Due to TEAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.
Time frame: From the start of study intervention (Day 1) up to 12 weeks
Part 2A: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date.
Time frame: From the start of study intervention (Day 1) up to 6 weeks
Part 2B: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.
Time frame: From the start of study intervention (Day 1) up to 9 weeks
Part 3: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset or worsen date was on or after study intervention start date. Data for the placebo or GSK3965193 monotherapy phase were presented.
Time frame: From the start of study intervention (Day 1) up to 6 weeks
Part 4: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE would be considered treatment emergent if the AE onset or worsen date was on or after study intervention start date.
Time frame: From the start of study intervention (Day 1) up to 48 weeks
Part 1: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, RBC indices (mean corpuscular volume \[MCV\] and mean corpuscular hemoglobin \[MCH\]), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), blood urea nitrogen (BUN), creatinine, glucose (non-fasting), potassium, sodium, calcium, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator.
Time frame: At Day 2
Part 2A: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.
Time frame: Up to 21 days
Part 2B: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.
Time frame: Up to 9 weeks
Part 3: Number of Participants With Clinically Significant Hematology and Clinical Chemistry Parameters
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
Time frame: Up to 35 days
Part 3: Number of Participants With Clinically Significant Urinalysis Parameters
Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
Time frame: Up to 28 days
Part 4: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters
Blood samples were planned to be collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was planned to be performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters would be determined by the investigator.
Time frame: Up to 48 weeks
Part 1: Number of Participants With Clinically Significant Vital Sign Findings
Vital signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.
Time frame: Up to 12 weeks
Part 2A: Number of Participants With Clinically Significant Vital Sign Findings
Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.
Time frame: Up to 21 days
Part 2B: Number of Participants With Clinically Significant Vital Sign Findings
Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.
Time frame: Up to 9 weeks
Part 3: Number of Participants With Clinically Significant Vital Sign Findings
Vital signs included temperature, SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
Time frame: Up to 35 days
Part 4: Number of Participants With Clinically Significant Vital Signs Findings
Vital signs were planned to include temperature, SBP and DBP, pulse and respiratory rate and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings would be determined by the investigator.
Time frame: Up to 48 weeks
Part 1: Number of Participants With Clinically Significant Electrocardiogram [ECG] Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of ECG parameters was determined by the investigator.
Time frame: Up to 12 weeks
Part 2A: Number of Participants With Clinically Significant ECG Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator.
Time frame: Up to 21 days
Part 3: Number of Participants With Clinically Significant ECG Findings
A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
Time frame: Up to 35 days
Part 4: Number of Participants With Clinically Significant ECG Findings
A 12-lead ECG was planned to be recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters planned to be collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG findings would be determined by the investigator.
Time frame: Up to 25 weeks
Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 7
Sensory nerve conduction testing was performed to detect neuropathy in participants. Nerve conduction velocity (NCV) and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25 percent (%) decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 7 was reported.
Time frame: Baseline and Day 7
Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 14
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 14 was reported.
Time frame: Baseline and Day 14
Part 2A: Number of Participants With Changes in Sensory Nerve Conduction at Day 42
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 42 was reported.
Time frame: Baseline and Day 42
Part 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 15
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 15 for the placebo or GSK3965193 monotherapy phase was reported.
Time frame: Baseline and Day 15
Part 3: Number of Participants With Changes in Sensory Nerve Conduction at Day 29
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 29 for the placebo or GSK3965193 monotherapy phase was reported.
Time frame: Baseline and Day 29
Part 4: Number of Participants With Changes in Sensory Nerve Conduction
Sensory nerve conduction testing was planned to be performed to detect neuropathy in participants. NCV and nerve conduction amplitude were planned to be determined. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from baseline was planned to be reported.
Time frame: Baseline up to 29 days
Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3965193 Following Single Dose Administration
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours (h) post-dose
Part 2A: AUC Over the Dosing Interval Tau (AUC[0-tau]) of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods. As the dosing interval Tau was 12 hours, AUC(0-tau) is the same as AUC from time zero to 12 hours after dosing (AUC\[0-12\]).
Time frame: Pre-dose and 15 minutes (min), 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, and 12 h post-first dose on Day 14
Part 1: Maximum Observed Concentration (Cmax) of GSK3965193 Following Single Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose
Part 2A: Cmax of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14
Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3965193 Following Single Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose
Part 2A: Tmax of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14
Part 1: Apparent Terminal Half-life (T1/2) of GSK3965193 Following Single Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours post-dose
Part 2A: T1/2 of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4, h, 8 h, and 12 h post-first dose on Day 1; pre-morning dose on Days 2 through 6 and Days 12 through 13; pre-dose and 15 min, 30 min, 1 h, 2h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h post-first dose on Day 14
Part 3: Maximum Reduction of Serum HBsAg Levels From Baseline
Blood samples were collected from participants to assess HBsAg levels for the placebo or GSK3965193 monotherapy phase. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Posterior mean and associated 95 percent (%) credible interval were derived for maximum reduction of serum HBsAg levels from Baseline using Bayesian mixed model repeated measures. The data presented are mean referring to posterior mean, with 95% confidence interval referring to 95% credible interval.
Time frame: From Baseline (Pre-dose on Day 1) up to 6 weeks
Part 4: Number of Participants Achieving Complete Response
Blood samples were planned to be collected to assess HBsAg and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Complete response is defined HBsAg and HBV DNA below lower limit of quantification (LLOQ) for 6 consecutive months after the planned end of treatment.
Time frame: Up to 48 weeks
Part 2B: AUC(0-inf) of GSK3965193 Following Single Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, and 72 h post-dose
Part 2B: Cmax of GSK3965193 Following Single Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 48 h, and 72 h post-dose
Part 3: AUC(0-tau) of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28
Part 3: Cmax of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28
Part 3: Tmax of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28
Part 3: T1/2 of GSK3965193 Following Repeat Dose Administration
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 1; pre-dose on Day 4, Day 8, Day 11, Day 15, Day 22; pre-dose and 0.25 h, 0.5 h, 1 h, 2, h, 3 h, 4 h, 6 h, 8 h, and 12 h post-dose on Day 28
Part 3: Number of Participants With Greater Than or Equal to [≥] 0.5 Times Log International Units Per Milliliters [IU/mL] Reduction From Baseline in Serum HBsAg Levels
Blood samples were collected from participants at indicated time points to assess HBsAg levels.
Time frame: From Baseline (Day 1) up to 42 days
Part 3: Number of Participants With TEAEs, STEAEs, and Treatment Withdrawals Due to TEAEs Among Participants Opting for Optional Bepirovirsen Treatment
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator.
Time frame: From the start of study intervention up to 54 weeks
Part 3: Number of Participants With Clinically Significant Hematology, Clinical Chemistry, and Urinalysis Parameters Among Participants Opting for Optional Bepirovirsen Treatment
Blood samples were planned to be collected to analyze clinical chemistry and hematology parameters: hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium corrected for albumin, creatinine, glucose, potassium, and sodium. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Number of participants with clinically significant clinical chemistry, hematology, and urinalysis parameters were reported. Clinical significance was determined by the investigator.
Time frame: From Week 7 up to 54 weeks
Part 3: Number of Participants With Clinically Significant Vital Signs Among Participants Opting for Optional Bepirovirsen Treatment
Vital signs were planned to include temperature and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of vital signs was determined by the investigator.
Time frame: From Week 7 up to 54 weeks
Part 4: Number of Participants With HBsAg Loss
Blood samples were collected from participants at indicated time points to assess HBsAg levels. HBsAg loss is defined by two consecutive measurements of HBsAg below the LLOQ any time during the study (on-treatment and post-treatment).
Time frame: Up to 48 weeks
The study was planned to be conducted in 4 parts. Part 1, a crossover study, consisted of 2 cohorts (Cohorts 1 and 2). Part 2 consisted of 2 sub-parts: Part 2A was a parallel group study comprised of 3 cohorts (Cohorts 3, 4, and 5); and Part 2B was a crossover study comprised of 1 cohort (Cohort 6). Part 3 was a parallel group study comprised of 1 cohort (Cohort 7). Part 4 was planned to be a parallel group study comprised of 1 cohort (Cohort 8).
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 7 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 14 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 10 | 0 | 0 |
| Withdrew: Ongoing in optional bepirovirsen treatment part at the time of analysis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 9 | 0 | 0 |
| Withdrew: Sponsor's decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.
| Participants | Part 1: Cohorts 1 and 2 - Placebo | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 2 | 3 | 1 | 1 | 1 | 3 | 0 | 1 | 0 |
| Any STEAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment Withdrawals due to TEAEs | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date.
| Participants | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|---|
| Any TEAE | 4 | 6 | 4 | 4 |
| Any STEAE | 0 | 0 | 0 | 0 |
| Treatment Withdrawals due to TEAEs | 0 | 1 | 2 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset date was on or after study intervention start date (i.e., Day 1) till Day 5 after study intervention administration. Any AE which started post Day 5 of study intervention administration was not considered as TEAE.
| Participants | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed |
|---|---|---|
| Any TEAE | 3 | 1 |
| Any STEAE | 0 | 0 |
| Treatment Withdrawals due to TEAEs | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE was considered treatment emergent if the AE onset or worsen date was on or after study intervention start date. Data for the placebo or GSK3965193 monotherapy phase were presented.
| Participants | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| Any TEAE | 2 | 4 |
| Any STEAE | 0 | 0 |
| Withdrawals due to TEAEs | 0 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator. An AE would be considered treatment emergent if the AE onset or worsen date was on or after study intervention start date.
No measurements were reported for this outcome.
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, RBC indices (mean corpuscular volume \[MCV\] and mean corpuscular hemoglobin \[MCH\]), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), blood urea nitrogen (BUN), creatinine, glucose (non-fasting), potassium, sodium, calcium, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator.
| Participants | Part 1: Cohorts 1 and 2 - Placebo | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|---|
| Hematology | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Clinical Chemistry | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.
| Participants | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|---|
| Hematology | 0 | 0 | 0 | 0 |
| Clinical Chemistry | 0 | 0 | 0 | 0 |
| Urinalysis | 0 | 0 | 0 | 0 |
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator.
| Participants | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed |
|---|---|---|
| Hematology | 0 | 0 |
| Clinical Chemistry | 0 | 0 |
| Urinalysis | 0 | 0 |
Blood samples were collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
| Participants | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| Hematology | 0 | 0 |
| Clinical Chemistry | 1 | 0 |
Urine samples were analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
| Participants | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| Part 3: Number of Participants With Clinically Significant Urinalysis Parameters | 0 | 0 |
Blood samples were planned to be collected to analyze hematology and clinical chemistry parameters: platelet count, RBC count, hemoglobin, hematocrit, RBC indices (MCV and MCH), WBC count with differential (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), BUN, creatinine, glucose (non-fasting), potassium, sodium, calcium, AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin, indirect bilirubin, direct bilirubin, total protein, and albumin. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was planned to be performed if abnormal blood or protein was present in the urine sample. Clinical significance of laboratory parameters would be determined by the investigator.
No measurements were reported for this outcome.
Vital signs included systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.
| Participants | Part 1: Cohorts 1 and 2 - Placebo | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Vital Sign Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.
| Participants | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|---|
| Part 2A: Number of Participants With Clinically Significant Vital Sign Findings | 0 | 0 | 1 | 0 |
Vital signs included SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator.
| Participants | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed |
|---|---|---|
| Part 2B: Number of Participants With Clinically Significant Vital Sign Findings | 0 | 0 |
Vital signs included temperature, SBP and DBP, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
| Participants | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| Part 3: Number of Participants With Clinically Significant Vital Sign Findings | 0 | 0 |
Vital signs were planned to include temperature, SBP and DBP, pulse and respiratory rate and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of the vital sign findings would be determined by the investigator.
No measurements were reported for this outcome.
A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of ECG parameters was determined by the investigator.
| Participants | Part 1: Cohorts 1 and 2 - Placebo | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Electrocardiogram [ECG] Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator.
| Participants | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|---|
| Part 2A: Number of Participants With Clinically Significant ECG Findings | 0 | 0 | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG parameters was determined by the investigator. Data for the placebo or GSK3965193 monotherapy phase were presented.
| Participants | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| Part 3: Number of Participants With Clinically Significant ECG Findings | 0 | 0 |
A 12-lead ECG was planned to be recorded with the participant in a semi-supine position after 5 minutes of rest using an ECG machine. The parameters planned to be collected were PR, QRS, QT, and QTc intervals. Clinical significance of ECG findings would be determined by the investigator.
No measurements were reported for this outcome.
Sensory nerve conduction testing was performed to detect neuropathy in participants. Nerve conduction velocity (NCV) and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25 percent (%) decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 7 was reported.
| Participants | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|---|
| 25% decrease in nerve conduction velocity | 0 | 0 | 0 | 0 |
| 50% decrease in nerve conduction amplitude | 0 | 0 | 1 | 0 |
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 14 was reported.
| Participants | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|---|
| 25% decrease in nerve conduction velocity | 0 | 0 | 0 | — |
| 50% decrease in nerve conduction amplitude | 0 | 0 | 0 | — |
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. Sensory nerve conduction studies at Baseline were collected twice, one at the time of screen and one prior to dosing. Mean (arithmetic mean) of two measurements were considered as Baseline. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 42 was reported.
| Participants | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|---|
| 25% decrease in nerve conduction velocity | 0 | 0 | 0 | — |
| 50% decrease in nerve conduction amplitude | 0 | 0 | 0 | — |
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 15 for the placebo or GSK3965193 monotherapy phase was reported.
| Participants | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| 25% decrease in nerve conduction velocity | 0 | 0 |
| 50% decrease in nerve conduction amplitude | 0 | 0 |
Sensory nerve conduction testing was performed to detect neuropathy in participants. NCV and nerve conduction amplitude were determined. The best measurement out of Screening and Day -1 was considered as Baseline, best being the higher measurement. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from Baseline at Day 29 for the placebo or GSK3965193 monotherapy phase was reported.
| Participants | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| 25% decrease in nerve conduction velocity | 0 | 0 |
| 50% decrease in nerve conduction amplitude | 0 | 0 |
Sensory nerve conduction testing was planned to be performed to detect neuropathy in participants. NCV and nerve conduction amplitude were planned to be determined. Number of participants with 25% decrease in NCV and 50% decrease in nerve conduction amplitude from baseline was planned to be reported.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
| Hours*nanograms per milliliter | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|
| Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3965193 Following Single Dose Administration | 1.95 ± 20.31 | 7.46 ± 20.21 | 14.50 ± 15.24 | 47.35 ± 15.72 | 147.02 ± 26.27 | 412.52 ± 23.01 | 1675.39 ± 29.13 | 3207.43 ± 34.82 |
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods. As the dosing interval Tau was 12 hours, AUC(0-tau) is the same as AUC from time zero to 12 hours after dosing (AUC\[0-12\]).
| Hours*nanograms per milliliter | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|
| Day 1 | 54.16 ± 18.53 | 123.78 ± 14.85 | 296.23 ± 15.40 |
| Day 14 | 83.76 ± 27.13 | 185.44 ± 31.76 | — |
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
| Nanograms per milliliter | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|
| Part 1: Maximum Observed Concentration (Cmax) of GSK3965193 Following Single Dose Administration | 0.26 ± 14.75 | 1.05 ± 22.02 | 2.24 ± 16.85 | 8.43 ± 14.05 | 25.08 ± 11.65 | 81.00 ± 13.38 | 247.21 ± 21.43 | 504.23 ± 24.24 |
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
| Nanograms per milliliter | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|
| Day 1 | 10.38 ± 29.16 | 22.93 ± 18.19 | 72.56 ± 22.24 |
| Day 14 | 13.71 ± 10.84 | 28.10 ± 32.46 | — |
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|
| Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3965193 Following Single Dose Administration | 0.50 (0.5 to 2.0) | 0.51 (0.3 to 2.0) | 0.38 (0.3 to 1.0) | 0.38 (0.3 to 0.5) | 0.50 (0.3 to 0.5) | 0.38 (0.3 to 0.5) | 0.50 (0.5 to 1.0) | 0.50 (0.3 to 1.0) |
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|
| Day 1 | 0.38 (0.3 to 1.0) | 0.50 (0.3 to 2.0) | 0.38 (0.3 to 0.5) |
| Day 14 | 0.50 (0.5 to 0.5) | 0.50 (0.3 to 1.0) | — |
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 |
|---|---|---|---|---|---|---|---|---|
| Part 1: Apparent Terminal Half-life (T1/2) of GSK3965193 Following Single Dose Administration | 7.40 ± 1.732 | 7.17 ± 1.568 | 7.62 ± 1.061 | 7.92 ± 0.814 | 8.26 ± 1.415 | 7.57 ± 0.443 | 7.63 ± 0.561 | 7.57 ± 1.054 |
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
| Hours | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID |
|---|---|---|---|
| Day 1 | 5.53 ± 0.871 | 5.15 ± 1.199 | 4.26 ± 0.966 |
| Day 14 | 5.15 ± 1.108 | 5.52 ± 1.133 | — |
Blood samples were collected from participants to assess HBsAg levels for the placebo or GSK3965193 monotherapy phase. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Posterior mean and associated 95 percent (%) credible interval were derived for maximum reduction of serum HBsAg levels from Baseline using Bayesian mixed model repeated measures. The data presented are mean referring to posterior mean, with 95% confidence interval referring to 95% credible interval.
| Log10 international units per milliliter | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 |
|---|---|---|
| Part 3: Maximum Reduction of Serum HBsAg Levels From Baseline | 0.075 (0.0512 to 0.0947) | 0.508 (0.2913 to 0.6924) |
Blood samples were planned to be collected to assess HBsAg and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Complete response is defined HBsAg and HBV DNA below lower limit of quantification (LLOQ) for 6 consecutive months after the planned end of treatment.
No measurements were reported for this outcome.
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Results for this outcome have not been posted.
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Results for this outcome have not been posted.
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Results for this outcome have not been posted.
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Results for this outcome have not been posted.
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Results for this outcome have not been posted.
Blood samples were collected at indicated time points for PK analysis of GSK3965193. PK analysis was conducted using standard non-compartmental methods.
Results for this outcome have not been posted.
Blood samples were collected from participants at indicated time points to assess HBsAg levels.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any serious adverse event that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; abnormal pregnancy outcomes or other situations as per the medical or scientific judgment of the investigator.
Results for this outcome have not been posted.
Blood samples were planned to be collected to analyze clinical chemistry and hematology parameters: hemoglobin, leukocytes, lymphocytes/leukocytes, neutrophils/leukocytes, platelets, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red blood cells, reticulocytes, ALT, albumin, alkaline phosphatase, AST, bilirubin, calcium corrected for albumin, creatinine, glucose, potassium, and sodium. Urine samples were planned to be analyzed using automated urinalysis or urine dipstick. Microscopic examination was performed if abnormal blood or protein was present in the urine sample. Number of participants with clinically significant clinical chemistry, hematology, and urinalysis parameters were reported. Clinical significance was determined by the investigator.
Results for this outcome have not been posted.
Vital signs were planned to include temperature and were planned to be measured with the participant in semi-supine position after 5 minutes rest. Clinical significance of vital signs was determined by the investigator.
Results for this outcome have not been posted.
Blood samples were collected from participants at indicated time points to assess HBsAg levels. HBsAg loss is defined by two consecutive measurements of HBsAg below the LLOQ any time during the study (on-treatment and post-treatment).
Results for this outcome have not been posted.
Collected over All-cause mortality, non-serious TEAEs and STEAEs were collected up to 12 weeks for Part 1, 6 weeks for Part 2A, 9 weeks for Part 2B, and 6 weeks in Part 3.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohorts 1 and 2 - Placebo | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Part 1: Cohort 1 - GSK3965193 Dose 1 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1: Cohort 1 - GSK3965193 Dose 2 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Cohort 1 - GSK3965193 Dose 3 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Cohort 1 - GSK3965193 Dose 4 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Cohort 2 - GSK3965193 Dose 5 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part 1: Cohort 2 - GSK3965193 Dose 6 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 1: Cohort 2 - GSK3965193 Dose 7 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Cohort 2 - GSK3965193 Dose 8 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 2A: Placebo | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed | 0/13 (0%) | 0/13 (0%) | 1/13 (7.7%) |
| Part 3: Cohort 7 - Placebo | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part 3: Cohort 7 - GSK3965193 Dose 9 | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| Part 4: Cohort 8 - Placebo + Bepirovirsen | — | — | — |
| Part 4: Cohort 8 - GSK3965193 + Bepirovirsen | — | — | — |
| Event | Part 1: Cohorts 1 and 2 - Placebo | Part 1: Cohort 1 - GSK3965193 Dose 1 | Part 1: Cohort 1 - GSK3965193 Dose 2 | Part 1: Cohort 1 - GSK3965193 Dose 3 | Part 1: Cohort 1 - GSK3965193 Dose 4 | Part 1: Cohort 2 - GSK3965193 Dose 5 | Part 1: Cohort 2 - GSK3965193 Dose 6 | Part 1: Cohort 2 - GSK3965193 Dose 7 | Part 1: Cohort 2 - GSK3965193 Dose 8 | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/16 | 2/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 1/6 | 4/6 | 1/7 | 1/4 | 1/11 | 0/13 | 0/4 | 2/14 | — | — |
| FatigueGeneral disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 2/6 | 0/7 | 2/4 | 0/11 | 0/13 | 0/4 | 3/14 | — | — |
| Brain fogNervous system disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 3/6 | 0/7 | 0/4 | 0/11 | 0/13 | 0/4 | 0/14 | — | — |
| TinnitusEar and labyrinth disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/7 | 0/4 | 0/11 | 0/13 | 0/4 | 0/14 | — | — |
| Post procedural complicationInjury, poisoning and procedural complications | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/7 | 0/4 | 0/11 | 0/13 | 0/4 | 0/14 | — | — |
| DysgeusiaNervous system disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/7 | 0/4 | 0/11 | 0/13 | 0/4 | 2/14 | — | — |
| NightmarePsychiatric disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/7 | 0/4 | 0/11 | 0/13 | 0/4 | 0/14 | — | — |
| DizzinessNervous system disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/7 | 0/4 | 0/11 | 0/13 | 0/4 | 4/14 | — | — |
| NauseaGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/7 | 1/4 | 0/11 | 0/13 | 0/4 | 1/14 | — | — |
| Feeling abnormalGeneral disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 1/4 | 0/11 | 0/13 | 0/4 | 0/14 | — | — |
The study was terminated after completion of Part 3 as a strategic decision. Hence, no participants were enrolled in Part 4.
| Age, Customized(Participants) | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 to 55 years | 2 | 2 | 2 | 2 | 3 | 5 | 2 | 2 | 6 | 6 | 7 | 4 | 6 | 7 | 3 | 13 | 0 | 0 | 72 |
| 56 to 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Sex: Female, Male(Participants) | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 4 |
| Male | 2 | 2 | 2 | 2 | 3 | 5 | 2 | 2 | 6 | 6 | 7 | 4 | 6 | 7 | 4 | 10 | 0 | 0 | 70 |
| Race/Ethnicity, Customized(Participants) | Part 1: Cohort 1 - Placebo/GSK3965193 Dose 2/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Placebo/Dose 3/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Placebo/Dose 4 | Part 1: Cohort 1 - GSK3965193 Dose 1/Dose 2/Dose 3/Placebo | Part 1: Cohort 2 - Placebo/GSK3965193 Dose 6/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Placebo/Dose 7/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Placebo/Dose 8 | Part 1: Cohort 2 - GSK3965193 Dose 5/Dose 6/Dose 7/Placebo | Part 2A: Placebo | Part 2A: Cohort 5 - GSK3965193 Dose 9 BID | Part 2A: Cohort 3 - GSK3965193 Dose 5 BID | Part 2A: Cohort 4 - GSK3965193 Dose 6 BID | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fasted/Fed | Part 2B: Cohort 6 - GSK3965193 Dose 10 Fed/Fasted | Part 3: Cohort 7 - Placebo | Part 3: Cohort 7 - GSK3965193 Dose 9 | Part 4: Cohort 8 - Placebo + Bepirovirsen | Part 4: Cohort 8 - GSK3965193 + Bepirovirsen | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASIAN | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 10 | 0 | 0 | 16 |
| BLACK OR AFRICAN AMERICAN | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 4 | 1 | 3 | 0 | 0 | 13 |
| WHITE | 2 | 0 | 1 | 2 | 3 | 3 | 2 | 0 | 6 | 5 | 6 | 3 | 6 | 3 | 2 | 1 | 0 | 0 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Apr 2022 to primary completion in May 2025, 37 months.
Results were first posted in Jun 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bepirovirsen